Hostname: page-component-6766d58669-zlvph Total loading time: 0 Render date: 2026-05-19T08:27:35.788Z Has data issue: false hasContentIssue false

Valuing Mortality Risk Reductions in Global Benefit-Cost Analysis

Published online by Cambridge University Press:  15 January 2019

Lisa A. Robinson*
Affiliation:
Harvard T.H. Chan School of Public Health, Center for Health Decision Science and Center for Risk Analysis, 718 Huntington Avenue, Boston, Massachusetts 02115, USA, e-mail: robinson@hsph.harvard.edu
James K. Hammitt
Affiliation:
Harvard T.H. Chan School of Public Health, Center for Health Decision Science and Center for Risk Analysis, 718 Huntington Avenue, Boston, Massachusetts 02115, USA Toulouse School of Economics, Université Toulouse Capitole, 21, allée de Brienne, 31000 Toulouse, France, e-mail: jkh@harvard.edu
Lucy O’Keeffe
Affiliation:
Harvard T.H. Chan School of Public Health, Center for Health Decision Science, 718 Huntington Avenue, Boston, Massachusetts 02115, USA, e-mail: okeeffe@hsph.harvard.edu
Rights & Permissions [Opens in a new window]

Abstract

The estimates used to value mortality risk reductions are a major determinant of the benefits of many public health and environmental policies. These estimates (typically expressed as the value per statistical life, VSL) describe the willingness of those affected by a policy to exchange their own income for the risk reductions they experience. While these values are relatively well studied in high-income countries, less is known about the values held by lower-income populations. We identify 26 studies conducted in the 172 countries considered low- or middle-income in any of the past 20 years; several have significant limitations. Thus there are few or no direct estimates of VSL for most such countries. Instead, analysts typically extrapolate values from wealthier countries, adjusting only for income differences. This extrapolation requires selecting a base value and an income elasticity that summarizes the rate at which VSL changes with income. Because any such approach depends on assumptions of uncertain validity, we recommend that analysts conduct a standardized sensitivity analysis to assess the extent to which their conclusions change depending on these estimates. In the longer term, more research on the value of mortality risk reductions in low- and middle-income countries is essential.

Information

Type
Article
Creative Commons
Creative Common License - CCCreative Common License - BY
This is an Open Access article, distributed under the terms of the Creative Commons Attribution licence (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted re-use, distribution, and reproduction in any medium, provided the original work is properly cited.
Copyright
© Society for Benefit-Cost Analysis 2019
Figure 0

Table 1 Comparison of VSL to GNI per capita: U.S. and OECD.

Figure 1

Table 2 Recent recommendations for estimating VSL in low- and middle-income countries.a

Figure 2

Figure 1 Selection criteria.

Figure 3

Figure 2 Ratio of VSL to GNI per capita (GNIpc).24

Figure 4

Table 3 Examples of extrapolated VSL estimates using alternative approaches.

Figure 5

Table A1 VSL studies conducted in low- and middle-income countries.

Figure 6

Table B1 Relationship of VSL estimates to GNI per capita.

Supplementary material: File

Robinson et al. supplementary material

Robinson et al. supplementary material 1

Download Robinson et al. supplementary material(File)
File 20.6 KB